Moberg Derma Initiates New Study of MOB-015
11/8/2012 9:52:42 AM
Moberg Derma AB (OMX: MOB) today announces that it has received the final
results from a phase II study of MOB-015 in patients with onychomycosis. The
clinical efficacy was unsatisfactory, and the company has therefore decided to
initiate a new study with an improved formulation.